Published ·
Real-time visibility turns pharma logistics into active risk management
Location, temperature, status and timing data create value only when they reveal exceptions early and trigger a documented decision.
Tracking shows location; visibility shows required action
Starting point: Why Real-Time Visibility Is Becoming Critical in Pharma Logistics, published 26.08.2026. This analysis transfers only the relevant principle to GDP warehousing and distribution; it does not copy text or service claims.
An industry article dated 26 August 2026 describes the move from basic shipment status to combined location, ETA, handover, route, temperature and exception information. For medicines, the key question is whether an event can affect product quality, availability or the next process step.
Warehouse and transport need one event chain
Goods receipt, stock status, batch, expiry, FEFO, picking, packing control and transport handover should not remain separate information islands. Shared timestamps and unambiguous statuses create traceability from warehouse location to consignee.
From alert to documented GDP decision
An alert is not yet a quality decision. The QMS needs risk criteria, roles, escalation and documented action. GDP remains the framework; digital signals may enable earlier detection but do not replace qualification or professional assessment.
Inter-Pharma turns data into controlled operations
At Cheb, Inter-Pharma connects warehousing, inventory, picking, dispatch preparation and European distribution. We structure data points, responsibilities, deviation workflows and KPI so visibility results in a specific, auditable action.
Frequently asked questions
What goes beyond traditional tracking?
Context combining status, time, route, handover and temperature where applicable.
Does monitoring replace GDP assessment?
No. Monitoring supplies signals; documented assessment follows defined roles and risk criteria.